Table 1.
Patient characteristics.
| Characteristics | Total | Underweight | Normal-weight | Overweight |
|---|---|---|---|---|
| Age, median (IQR), y | 60.0 (53-67) | 59.0 (54-70) | 60.0 (52-67) | 61.0 (54-67) |
| Male | 385 (71.2%) | 17 (58.6%) | 225 (66.8%) | 143 (81.7%) |
| BMI, median (IQR), kg/m² | 23.4 (21.3-25.6) | 17.4 (16.6-18.0) | 22.2 (20.9-23.7) | 26.4 (25.7-28.1) |
| Tobacco | ||||
| Never | 291 (53.8%) | 15 (51.7%) | 188 (55.8%) | 88 (50.3%) |
| Former | 115 (21.3%) | 5 (17.2%) | 71 (21.1%) | 39 (22.3%) |
| Current | 135 (25.0%) | 9 (31.0%) | 78 (23.1%) | 48 (27.4%) |
| Neoadjuvant chemotherapy | 157 (29.0%) | 8 (27.6%) | 104 (30.9%) | 45 (25.7%) |
| Tumor location | ||||
| Lower third | 290 (53.6%) | 17 (58.6%) | 193 (57.3%) | 80 (45.7%) |
| Middle third | 147 (27.2%) | 4 (13.8%) | 95 (28.2%) | 48 (27.4%) |
| Upper third | 104 (19.2%) | 8 (27.6%) | 49 (14.5%) | 47 (26.9%) |
| Tumor size, median (IQR), cm | 3.0 (2.0-4.0) | 3.5 (2.5-5.2) | 3.0 (2.0-4.5) | 2.5 (2.0-4.0) |
| Tumor grade | ||||
| Poorly differentiated | 377 (69.7) | 21 (72.4) | 244 (72.4) | 112 (64.0) |
| Well-moderately differentiated | 164 (30.3) | 8 (27.6) | 93 (27.6) | 63 (36.0) |
| T stage | ||||
| T1 | 186 (34.4) | 8 (27.6) | 106 (31.5) | 72 (41.1) |
| T2 | 86 (15.9) | 4 (13.8) | 54 (16.0) | 28 (16.0) |
| T3 | 170 (31.4) | 11 (37.9) | 105 (31.2) | 54 (30.9) |
| T4 | 99 (18.3) | 6 (20.7) | 72 (21.4) | 21 (12.0) |
| Lymph node metastasis | ||||
| No | 286 (52.9) | 12 (41.4) | 164 (48.7) | 110 (62.9) |
| Yes | 255 (47.1) | 17 (58.6) | 173 (51.3) | 65 (37.1) |
| Distant metastasis | ||||
| No | 530 (98.0) | 28 (96.6) | 329 (97.6) | 173 (98.9) |
| Yes | 11 (2.0) | 1 (3.4) | 8 (2.4) | 2 (1.1) |
| TNM Stage | ||||
| I | 220 (40.7%) | 8 (27.6%) | 124 (36.8%) | 88 (50.3%) |
| II | 146 (27.0%) | 9 (31.0%) | 97 (28.8%) | 40 (22.9%) |
| III | 164 (30.3%) | 11 (37.9%) | 108 (32.0%) | 45 (25.7%) |
| IV | 11 (2.0%) | 1 (3.4%) | 8 (2.4%) | 2 (1.1%) |
| Postoperative complications | ||||
| No | 419 (77.4) | 25 (86.2) | 270 (80.1) | 124 (70.9) |
| Yes | 122 (22.6) | 4 (13.8) | 67 (19.9) | 51 (29.1) |
| Adjuvant chemotherapy | 314 (58.0) | 13 (44.8) | 208 (61.7) | 93 (53.1) |
| Baseline splenic volume, median (IQR), ml | 167.0 (124.9-224.6) | 121.3 (86.9-153.5) | 159.7 (119.1-203.6) | 206.5 (154.1-252.4) |